Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

HIV Infection

Free Subscription 13.10.2025 14 AIDS 1 Antimicrob Agents Chemother 1 Antivir Ther 7 Clin Infect Dis 4 HIV Med 8 J Acquir Immune Defic Syndr 1 J Immunol 4 J Infect Dis 1 J Med Virol 2 J Virol 1 Lancet Infect Dis 1 Pediatr Infect Dis J 10 PLoS One 2 PLoS Pathog 1 Proc Natl Acad Sci U S A 2 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. KIMMEL AD, Pan Z, Byrd KK, Stirratt M, et al
   Validity of competing algorithms to identify people with HIV in Medicaid administrative claims: a statewide analysis.
   AIDS. 2025 Oct 8. doi: 10.1097/QAD.0000000000004362.
   PubMed         Abstract available
   
   
2. KORPELA E, Dastgheyb RM, Letendre SL, Franklin DR Jr, et al
   Longitudinal effects of polypharmacy on cognitive function in people with HIV.
   AIDS. 2025 Oct 9. doi: 10.1097/QAD.0000000000004379.
   PubMed         Abstract available
   
   
3. VOLLMOND CV, Tetens MM, Gerstoft J, Kronborg G, et al
   Risk of schizophrenia spectrum disorders among people with HIV: A nationwide, populationbased, matched cohort study.
   AIDS. 2025 Oct 8. doi: 10.1097/QAD.0000000000004373.
   PubMed         Abstract available
   
   
4. DOGON C, Bengtson AM, Botha M, Burd T, et al
   Associations between maternal lipid profiles and cardiovascular and metabolic outcomes among children who are HIV-exposed uninfected versus HIV-unexposed children aged 5-8 years in a South African birth cohort.
   AIDS. 2025 Oct 8. doi: 10.1097/QAD.0000000000004377.
   PubMed         Abstract available
   
   
5. ELIAS RH, Holtrop J, Smit C, Dorresteijn JAN, et al
   Estimated 10-year risk of recurrent cardiovascular events and potential health benefits of secondary prevention in people with HIV.
   AIDS. 2025 Oct 8. doi: 10.1097/QAD.0000000000004375.
   PubMed         Abstract available
   
   
6. ABELMAN RA, Ma Y, Mehta CC, Yang Q, et al
   Menopause is associated with faster increases in insulin resistance in women with HIV.
   AIDS. 2025 Oct 8. doi: 10.1097/QAD.0000000000004378.
   PubMed         Abstract available
   
   
7. HAGINS D, Berhe M, Crofoot GE, Ramgopal MN, et al
   Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV: randomized study.
   AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004372.
   PubMed         Abstract available
   
   
8. FAHEY CA, Ruderman SA, Drumright LN, Fredericksen RJ, et al
   Association between housing instability and frailty among people with HIV.
   AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004370.
   PubMed         Abstract available
   
   
9. MOORE B, O'Connor S, Sato K, Briceno'Robaugh RI, et al
   Implementation of tuberculosis services for children living with HIV in PEPFAR-supported programs in 16 high TB/HIV-burden countries in sub-Saharan Africa, 2019-2022.
   AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004364.
   PubMed         Abstract available
   
   
10. KNUDSEN AD, Gelpi M, Suarez-Zdunek MA, Loft JA, et al
    Inhibition of Th1-type immune responses in persons with HIV with current statin exposure.
    AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004366.
    PubMed         Abstract available
    
    
11. HERNANDEZ-SANCHEZ D, Satorra P, Martinez A, Puig J, et al
    Muscular and plasma markers for early identification of frailty and sarcopenia states in people with HIV: results from the IMAGING study.
    AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004363.
    PubMed         Abstract available
    
    
12. JAO J, Gochanour C, Williams PL, Schenkel S, et al
    Pubertal onset in children with in utero HIV/antiretroviral exposure in Botswana.
    AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004374.
    PubMed         Abstract available
    
    
13. ELLIS RJ, Tang B, Heaton RK, Patel P, et al
    Predicting neurobehavioral outcomes in people with HIV.
    AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004365.
    PubMed         Abstract available
    
    
14. VAN STEYN JT, Dear N, Esber A, Frndak S, et al
    A retrospective analysis of maternal factors, access of prevention of vertical transmission resources, and infant preterm delivery and mortality.
    AIDS. 2025 Oct 7. doi: 10.1097/QAD.0000000000004371.
    PubMed         Abstract available
    
    

    
    Antimicrob Agents Chemother

15. SWANSTROM AE, Oswald K, Fast R, Shoemaker R, et al
    The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection.
    Antimicrob Agents Chemother. 2025 Oct 7:e0107325. doi: 10.1128/aac.01073.
    PubMed         Abstract available
    
    

    
    Antivir Ther

16. DE KOFF EM, van Andel H, de Jong HK, van der Kooi AJ, et al
    Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report.
    Antivir Ther. 2025;30:13596535251385624.
    PubMed         Abstract available
    
    

    
    Clin Infect Dis

17. BELSHE RB, Bernstein DI, Edwards KM, Frey SE, et al
    Vaccine and Treatment Evaluation Units: A Historical Perspective.
    Clin Infect Dis. 2025;81.
    PubMed         Abstract available
    
    
18. PANACCIONE S, Jack H, Wurcel A, Rich J, et al
    State-of-the-Art Review: The Intersection of Infectious Diseases and Carceral Medicine.
    Clin Infect Dis. 2025;81:e42-e51.
    PubMed         Abstract available
    
    
19. SCHWARTZ EL, Nalintya EK, Skipper CP, Nerima P, et al
    Predictive value of C-reactive protein for hospitalization and mortality among people with advanced HIV disease in Uganda receiving the WHO-recommended package of care.
    Clin Infect Dis. 2025 Oct 8:ciaf560. doi: 10.1093.
    PubMed         Abstract available
    
    
20. MARTINEZ E, Foncillas A, De la Mora L, Mallolas J, et al
    Advanced HIV Disease in the ICU: Experience from a Spanish Cohort.
    Clin Infect Dis. 2025 Oct 8:ciaf556. doi: 10.1093.
    PubMed        
    
    
21. TAN B, Krishnaswamy S, MacPhail A, Pilcher D, et al
    Role of local and population-based data in Advanced HIV Disease in the ICU.
    Clin Infect Dis. 2025 Oct 8:ciaf557. doi: 10.1093.
    PubMed        
    
    
22. SERRANO-VILLAR S, Martin-Pedraza L, Tiraboschi J, Novella M, et al
    Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study).
    Clin Infect Dis. 2025 Oct 10:ciaf565. doi: 10.1093.
    PubMed         Abstract available
    
    
23. DOBRZYNSKI DM, Graciaa DS, Babu TM, Coler RN, et al
    From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units.
    Clin Infect Dis. 2025;81.
    PubMed        
    
    

    
    HIV Med

24. WHITLOCK G, Cole S, Khurshid A, Boffito M, et al
    HIV prevention in London, UK, from 2017 to 2024: Outcomes, gaps and learnings.
    HIV Med. 2025;26:1612-1618.
    PubMed         Abstract available
    
    
25. CHAN P, Moreland S, Sacdalan C, Colby DJ, et al
    Blood pressure and metabolic outcomes after efavirenz- or dolutegravir-based therapy started in acute HIV infection.
    HIV Med. 2025;26:1619-1625.
    PubMed         Abstract available
    
    
26. SCHUETTFORT G, Borch J, Cabello A, Crusells M, et al
    Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.
    HIV Med. 2025 Oct 7. doi: 10.1111/hiv.70119.
    PubMed         Abstract available
    
    
27. WEIBULL WARNBERG A, Cena-Diez R, Sonnerborg A, van de Klundert MAA, et al
    Natural occurrence of drug resistance mutations to the HIV-1 capsid inhibitor lenacapavir.
    HIV Med. 2025 Aug 7. doi: 10.1111/hiv.70092.
    PubMed         Abstract available
    
    

    
    J Acquir Immune Defic Syndr

28. ROSENBERG NE, Young AM, Zou Y, Justman J, et al
    An HIV-1 risk assessment tool for men aged 15-59 years in 13 African countries: A pooled analysis of nationally representative surveys.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003773.
    PubMed         Abstract available
    
    
29. DAHAL S, Logan J, Kanagasabai U, Annor F, et al
    Differential associations of violence and mental health outcomes by HIV status among adolescent girls and young women aged 15-24 years in 5 countries in Sub-Saharan Africa, 2018/2019.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003769.
    PubMed         Abstract available
    
    
30. CEBULA BR, Frndak S, Hamby T, Esber A, et al
    COVID-19 Knowledge, Attitudes, and Practices among People with and Without HIV in Four Countries in Sub-Saharan Africa.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003770.
    PubMed         Abstract available
    
    
31. CHANDRAN A, Olson S, Edmonds A, Moran CA, et al
    Trajectories of BMI Before, During and Following the COVID-19 Pandemic among Participants in the MACS/WIHS Combined Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003779.
    PubMed         Abstract available
    
    
32. ALFORD K, Fitzpatrick C, Rhodes S, O'Brien C, et al
    Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway.
    J Acquir Immune Defic Syndr. 2025 Oct 8. doi: 10.1097/QAI.0000000000003775.
    PubMed         Abstract available
    
    
33. FIEGGEN J, Meintjes G, Boulle A, Euvrard J, et al
    Characteristics of Individuals with Advanced HIV Disease and Risk Factors for Mortality in a Contemporary Cohort in South Africa.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003767.
    PubMed         Abstract available
    
    
34. BHUSHAN NL, Boudewyns V, Getachew-Smith H, Stryker JE, et al
    Pre-Exposure Prophylaxis (PrEP) Guideline Awareness and Prescribing Behaviors Among Healthcare Providers in the United States: DocStyles Survey, 2022-2024.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003774.
    PubMed         Abstract available
    
    
35. STEVENSON M, Cooney E, Borquez A, Radix AE, et al
    Undiagnosed HIV among transgender women in the United States: Implications for testing programs.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003776.
    PubMed         Abstract available
    
    

    
    J Immunol

36. KOTTOM TJ, Limper AH
    Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies.
    J Immunol. 2025 Oct 6:vkaf269. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Infect Dis

37. SESAY FA, Oware K, Violette LR, Donnell D, et al
    Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.
    J Infect Dis. 2025 Oct 9:jiaf519. doi: 10.1093.
    PubMed         Abstract available
    
    
38. MALATESTA S, Carney T, Niemand Wolhuter N, Overbeck V, et al
    Tuberculosis Disease Prevalence Among People Who Smoke Illicit Drugs: A Respondent- Driven Sampling Study in the Western Cape, South Africa.
    J Infect Dis. 2025 Oct 8:jiaf481. doi: 10.1093.
    PubMed         Abstract available
    
    
39. MOONAN PK, Mathew SO, Simecka JW, Weis SE, et al
    Restoring TB-specific immunity in early HIV infection-the dual promise of early antiretroviral and TB preventive treatment.
    J Infect Dis. 2025 Oct 6:jiaf518. doi: 10.1093.
    PubMed        
    
    
40. WARD M, Zumbo P, Joseph Y, Apollon A, et al
    Increased plasmacytoid dendritic cells and inflammation persist in people with HIV years after tuberculosis.
    J Infect Dis. 2025 Oct 7:jiaf499. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Med Virol

41. YUNIHASTUTI E, Ophinni Y, Sari V, Adli I, et al
    Longitudinal Changes in Immune Biomarkers Following Direct-Acting Antiviral Therapy in HIV/HCV-Coinfected Individuals in Indonesia.
    J Med Virol. 2025;97:e70627.
    PubMed         Abstract available
    
    

    
    J Virol

42. MEDICA S, Diggins NL, Denton M, Turner RL, et al
    Human cytomegalovirus UL78 is a nuclear-localized GPCR necessary for efficient reactivation from latent infection in CD34(+) hematopoietic progenitor cells.
    J Virol. 2025 Oct 8:e0140225. doi: 10.1128/jvi.01402.
    PubMed         Abstract available
    
    
43. MITCHELL JK, Mastrodomenico V, Hartnett J, Heelan WJ, et al
    A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification of virus neutralization and antibody-dependent enhancement.
    J Virol. 2025 Oct 8:e0099125. doi: 10.1128/jvi.00991.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

44. SUNG J, Nantale M, Nalutaaya A, Biche P, et al
    Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study.
    Lancet Infect Dis. 2025 Oct 7:S1473-3099(25)00536.
    PubMed         Abstract available
    
    

    
    Pediatr Infect Dis J

45. CAGLAR I, Bag O, Yilmaz Celebi M, Kiymet E, et al
    Evaluation of Adherence to HIV Postexposure Prophylaxis and Follow-up in Pediatric Sexual Assault Victims in Turkey: A Tertiary Center Experience.
    Pediatr Infect Dis J. 2025 Oct 8. doi: 10.1097/INF.0000000000004984.
    PubMed         Abstract available
    
    

    
    PLoS One

46. SOHAIL M, Westfall AO, Chiedo A, Johnson B, et al
    Contextual barriers to PrEP uptake and continuation among young Black gay and bisexual men who have sex with men living in the South.
    PLoS One. 2025;20:e0334285.
    PubMed         Abstract available
    
    
47. ZHANG CR, Wang M, Wang L, Liu L, et al
    Differential composition of the pulmonary microbiome in HIV-positive versus HIV-negative patients with Pneumocystis jirovecii.
    PLoS One. 2025;20:e0334220.
    PubMed         Abstract available
    
    
48. GOBEZIE MY, Hassen M, Solomon T, Demessie MB, et al
    Carriage rates and antimicrobial resistance of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0333054.
    PubMed         Abstract available
    
    
49. XI M, Bullock S, Mendelsohn JB, Moravan V, et al
    The impact of Undetectable=Untransmittable and viral suppression on condomless sex among mixed HIV-status couples in Canada.
    PLoS One. 2025;20:e0332926.
    PubMed         Abstract available
    
    
50. NZOBOKELA J, Muchaili L, Kamvuma K, Mweene BC, et al
    Pro-inflammation and clinical correlates of unsuppressed HIV-viral load in children living with perinatally-acquired HIV 1 in Zambia.
    PLoS One. 2025;20:e0334109.
    PubMed         Abstract available
    
    
51. COSTA SANTOS A, Paim JN, de Soarez PC, Cerchiari N, et al
    Costs and return to scale analysis of extending the offer of pre-exposure prophylaxis (PrEP) to key populations aged 15-17 years old in two Brazilian cities.
    PLoS One. 2025;20:e0332901.
    PubMed         Abstract available
    
    
52. ZURASHVILI T, Pashalishvili M, Earnshaw VA, Do H, et al
    Disclosing HIV status to sexual partner: Findings from a People Living with HIV Stigma Index 2.0 study in the country Georgia.
    PLoS One. 2025;20:e0331919.
    PubMed         Abstract available
    
    
53. ADRIAN H, Dijkstra M, Mahmoud S, Mohamed K, et al
    Peer-assisted HIV partner notification services to strengthen index partner testing for newly diagnosed men who have sex with men in coastal Kenya.
    PLoS One. 2025;20:e0333707.
    PubMed         Abstract available
    
    
54. RENNIE S, Onyeama U, Sullivan K, Day S, et al
    Consent in the practice of molecular HIV epidemiology: A qualitative study of the perspectives of diverse communities of interest.
    PLoS One. 2025;20:e0330733.
    PubMed         Abstract available
    
    
55. GONZALEZ-RECIO P, Barba-Sanchez R, Granda E, Guerras JM, et al
    From fear of infection to awareness against stigma: A mixed-methods analysis of discourses on HIV in a parliamentary context.
    PLoS One. 2025;20:e0333537.
    PubMed         Abstract available
    
    

    
    PLoS Pathog

56. ALDUNATE M, Tyssen D, Johnson A, Latham CF, et al
    Lactic acid produced by optimal vaginal Lactobacillus spp. potently and specifically inactivates HIV-1 in vitro by targeting the viral RNA genome and reverse transcriptase.
    PLoS Pathog. 2025;21:e1013594.
    PubMed         Abstract available
    
    
57. AHMAD I, Zhang J, Li R, Su W, et al
    Murine leukemia virus glycoGag antagonizes SERINC5 via ER-phagy receptor RETREG1.
    PLoS Pathog. 2025;21:e1013023.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

58. VADON C, Nguyen XN, Siahaan V, Song Y, et al
    Microtubule remodeling by the innate immune factor Trim69 compromises dynein-dependent migration of HIV virion cores toward the nucleus.
    Proc Natl Acad Sci U S A. 2025;122:e2505128122.
    PubMed         Abstract available
    
    

    
    Vaccine

59. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
    Corrigendum to "Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa" [Vaccine 64 (2025) 127770].
    Vaccine. 2025;65:127797.
    PubMed        
    
    
60. CLAY PA, Markowitz LE, Gopalani SV, Baxter A, et al
    HPV vaccination among gay, bisexual, and other men who have sex with men aged 27-45 years in the United States is potentially Cost-saving.
    Vaccine. 2025;65:127798.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.